ArticleFrontiers in oncology2024

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review.

Yuxin Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.